Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-07-14

Clinical Trial Update: Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma. [Phase 2]

View source ↗

Summary

Phase 2 trial update of lurbinectedin monotherapy in patients with progressive malignant pleural mesothelioma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Lurbinectedin (lurbinectedin)

Snippet

Sponsor: Swiss Cancer Institute | Conditions: Malignant Pleural Mesothelioma, Advanced | Phase 2 | Status: COMPLETED